MedPath

Mubodina

Generic Name
Mubodina
Drug Type
Biotech

Overview

Mubodina is an investigational drug developed by Adienne Pharma & Biotech. It is a recombinant human minibody directed against complement component C5. It was investigated in various conditions including primary membranoproliferative glomerulonephritis and typical hemolytic uremic syndrome.

Background

Mubodina is an investigational drug developed by Adienne Pharma & Biotech. It is a recombinant human minibody directed against complement component C5. It was investigated in various conditions including primary membranoproliferative glomerulonephritis and typical hemolytic uremic syndrome.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor

No clinical trials found

No clinical trials found for this drug

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.
© Copyright 2025. All Rights Reserved by MedPath